Anika Announces Plans to Showcase HYALOFAST at the International Cartilage Regeneration and Joint Preservation Society (ICRS) Summit in San Diego

From Startup Anika Therapeutics

Link to Full Article: http://ir.anikatherapeutics.com/news-releases/news-release-details/anika-announces-plans-showcase-hyalofast-international-cartilage

BEDFORD, Mass.–(BUSINESS WIRE)–Jan. 16, 2019–
Anika
Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic
and regenerative medicines company specializing in therapeutics based on
its proprietary hyaluronic
acid (“HA”) technology, today announced plans to showcase HYALOFAST,
a biodegradable, HA-based cartilage repair scaffold, at the 2019
International Cartilage Repair Society (ICRS) Summit. The 2019 ICRS
Summit, which will be focused on Bio-Orthopaedics in Sports Medicine,
will be held in San Diego, CA at the Hyatt Regency Mission Bay on
January 17-18, 2019.

At the 2019 ICRS Summit, Dr. Alberto Gobbi, world-renowned specialist in
arthroscopic surgery, cartilage repair and regenerative medicine, will
present findings from a 10-year follow-up study of patients treated with
HYALOFAST HA scaffold with Bone Marrow Aspirate Concentrate (BMAC) in a
one-step surgery. The session will also provide a comparative review of
HYALOFAST in comparison to ACI (Autologous Chondrocyte Implantation) and
MACI (Matrix Autologous Chondrocyte Implantation), two-step surgeries
requiring cell cultivation.

“The ICRS Summit in San Diego is a great opportunity to showcase the
significant advantages of HYALOFAST before an assembly of world-renowned
specialists in the field of cartilage repair and regeneration,” said
Joseph Darling, President and CEO, Anika Therapeutics. “We believe
that HYALOFAST is a truly remarkable advancement in the treatment of
cartilage injuries and defects due to its flexible, minimally-invasive
means of application and adaptive fit to individual patient needs.”

HYALOFAST is a non-woven, single-step, off-the-shelf, biodegradable
HA-based scaffold for hyaline-like cartilage regeneration to treat
cartilage injuries and defects. HYALOFAST is commercially available in
approximately 15 countries and has been used to successfully treat more
than 15,000 patients internationally, with strong ten-year patient
follow-up data. HYALOFAST is pending regulatory submission in the United
States following its FastTRACK Phase III trial which is currently
enrolling patients across the U.S. and Europe.

Technical Session 3: Cartilage

Title: “One or Two Steps: Long Term Results”Presenter: Dr. Alberto
Gobbi, OASI Bioresearch Foundation, Milano – ItalyDate/Time:
January 17, 2019 at 10:45 – 11:40am
Company-Sponsored Booth

Anika will be a Gold Sponsor and will host a booth (#6), where it will
showcase HYALOFAST.

About ICRS

The ICRS
(International Cartilage Regeneration and Joint Preservation Society) is
the main forum for international collaboration in cartilaginous tissue
research that brings together basic scientists, clinical researchers,
physicians and members of industry, engaged or interested in the field
of articular biology, its genetic basis and regenerative medicine. It
provides continuing education and training to physicians and scientists
with an active interest in the prevention and treatment of joint disease
to improve patient care through regenerative medicine approaches.

2018 HYALOFAST Publications

Gobbi A., et al. Use of bone marrow aspirate concentrate combined
with hyaluronan-based scaffold for early osteoarthritis in athletes.
Football Medicine Outcomes Abstract book XXVII Isokinetic Medical
Group International Conference – Camp Nou, Barcelona2-4 June 2018. Ed
Calzetti & Mariucci. Page 442.

Sofu H. et al. Clinical and radiographic outcomes of
chitosan-glycerol phosphate/blood implant are similar with hyaluronic
acid-based cell-free scaffold in the treatment of focal osteochondral
lesions of the knee joint. Knee Surg Sports Traumatol Arthrosc.
2018 Aug 1. (Epub ahead of print).

Gollwitzer H. Operative Therapie – Knorpelschäden der Hϋfte
Einzeitiges arthroskopisches Verfahren zur Regeneration.
Sportärztezeitung 03/2018 (Cartilage Damage to the Hip. One-Stage
Arthroscopic Method of Regeneration).

About Anika Therapeutics, Inc.
Anika
Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated
orthopedic and regenerative medicines company based in Bedford,
Massachusetts. Anika is committed to improving the lives of patients
with degenerative orthopedic diseases and traumatic conditions with
clinically meaningful therapies along the continuum of care, from
palliative pain management to regenerative tissue repair. The Company
has over two decades of global expertise developing, manufacturing, and
commercializing more than 20 products based on its proprietary hyaluronic
acid (HA) technology. Anika’s orthopedic medicine portfolio
includes ORTHOVISC®, MONOVISC®,
and CINGAL®,
which alleviate pain and restore joint function by replenishing depleted
HA, and HYALOFAST,
a solid HA-based scaffold to aid cartilage repair and regeneration. For
more information about Anika, please visit www.anikatherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190116005053/en/
Source: Anika Therapeutics, Inc.

For Investor Inquiries:Anika Therapeutics, Inc.Sylvia
Cheung, 781-457-9000Chief Financial OfficerFor Media
Inquiries:W2O GroupSonal Vasudev, 917-523-1418sonal@w2ogroup.com

Please visit their site for more information: Anika Therapeutics.com

All,Biotechnology,Healthcare News,Startup News
2019-01-17 20:01:03